Antibodies, also called as immunoglobulin, are proteins produced by plasma cells in response to specific antigens. These antibodies can be used as therapeutic as well as diagnostic purposes for several disease indications, including but not limited to, non-Hodgkin lymphoma, rheumatoid arthritis, Crohn’s disease, psoriasis, hypercholesterolemia, macular degeneration, and asthma. Monoclonal antibodies is the most lucrative drug type segment for manufacturers of antibody-based drugs. Owing to large number of product launches, antibodies market is expected to witness steady growth during the forecast period 2016-2026. Technological advancement and availability of next-generation antibody products are also boosting the growth of the global antibodies market. Effective harmonisation of product development, registration and approval guidelines in major markets, such as the U.S. and EU could speed up the research and development of antibody based products.
Market Value Forecast
The global antibodies market is estimated to be valued at US$ 105,217.1 Mn in 2016 and is projected to grow at CAGR of 12.5% to reach US$ 341,373.6 Mn by 2026-end.
Global antibodies market is primarily driven by factors such as continuous launch of innovative products, high adoption rate of therapeutic antibodies in cost-sensitive markets, quick approval by regulatory authorities for breakthrough therapies, rise in chronic illnesses owing to population shift and increasing longevity, availability of inexpensive biosimilar antibody therapeutics, and adoption of diagnostic antibodies. Companies are adopting various strategies, such as expansion of product indications to sustain in the dynamically growing antibodies market.
The global antibodies market is expected to witness impressive growth over the forecast period. However, high cost of treatment and side effects associated with antibodies treatment can hinder the growth of global antibodies market.
Segmentation by Drug Type
The global antibodies market is segmented on the basis of drug type into monoclonal antibodies, polyclonal antibodies, and antibody-drug conjugates. Monoclonal antibodies product type segment accounted for the highest market share of 94.8% in 2015 and is expected to expand at CAGR of 12.6% over the forecast period.
Segmentation by Disease Application
Based on indication, the global market for antibodies is segmented into central nervous system (CNS) disorders, cardiovascular diseases, cancer and autoimmune disorders. Cancer indication type segment accounted for maximum market share in 2015 owing to vast application of monoclonal antibodies for the treatment of various cancers. Autoimmune disorders indication segment is expected to expand at the highest CAGR owing to increasing applications of antibody-based drugs for new immunological indications
Segmentation by End User
The global market for antibodies is segmented on the basis of end-user into hospitals, long-term care facilities, and research institutes. Hospitals account for the maximum market share in global antibodies market owing to requirement of advanced infrastructure for administering immunogenic agents such as monoclonal antibodies. Long-term care facilities end user segment is expected to experience significant growth due to increasing number of hospice patients being admitted for Alzheimer’s disease in the U.S.
By region, the global antibodies market has been segmented into North America, Latin America, Western Europe, Eastern Europe, Asia Pacific Excluding Japan (APEJ), Middle East & Africa (MEA) and Japan. North America contributed highest market share in global antibodies market in 2015, mainly due to necessity of addressing urgent unmet need in treatment of cancer and immunological diseases such as rheumatoid arthritis. North America antibodies market is expected to grow at highest CAGR of 13. 4% over the forecast period.
Some of the major players operating in global antibodies market include Novartis AG, F. Hoffmann-La Roche Ltd., Johnson & Johnson Services, Inc., Amgen Inc. Bristol-Myers Squibb Company, AbbVie Inc., Eli Lilly and Co. and others. F. Hoffmann-La Roche Ltd. was the global leader in the global antibodies market in 2015. The company offers a wide range of products in the antibodies market, including monoclonal antibodies, antibodies fusion proteins, bispecific antibodies and antibody drug conjugates. Flagship products of the company include Herceptin, Avastin, Rituxan and Lucentis.
Majority of the players are focused on co-development and co-marketing of products in order to enhance their market presence. Moreover, collaborations and partnerships also enable these companies to increase visibility of their products in markets across the concerned regions. Companies are also focusing on improving their competitive capabilities through strengthening of pipeline productivity.
Future market insights offers a 10-year forecast on the global market for antibodies between 2016 and 2026. The global antibodies market is expected to witness a robust CAGR of 12.5% over the forecast period. The study demonstrates market dynamics that are expected to influence the current environment and future status of the global antibodies market over the forecast period. The primary objective of this report is to offer updates on trends, drivers, restraints, value forecasts, and opportunities for manufacturers operating in the global antibodies market.
Global demand for antibodies is increasing with growing burden of chronic illnesses such as cancer, autoimmune disorders and others. Developed markets such as the U.S. and Europe are witnessing increasing demand for antibody-based drugs due to rising demand for better treatment options. To understand and analyse the market, the report is categorically split into four sections, viz. market analysis by drug type, end user, indication, and regions. The report analyses the global antibodies market in terms of value (US$ Mn).
The global antibodies market is segmented on the basis of
The report begins with the market definition and defining different product types. This is followed by the overview on evolution of antibody based drugs. The market dynamics section includes FMI’s analysis on key trends, drivers, restraints, opportunities and macro factors influencing global antibodies market. Impact analysis of key growth drivers and restraints based on weighted average model has also been included in the report to better equip clients with crystal clear decision making insights.
The next section of the report analyses the market based on drug type and presents the forecast in terms of value for the next 10 years. Drug types covered in the report include:
Monoclonal antibodies drug type segment holds highest market share in global antibodies market owing to high potential of these drugs for use in targeted therapies. Antibody-drug conjugates drug-type segment is expected to grow at significant CAGR over the forecast period due to unique property of exerting combined therapeutic effect of antibody and conjugated drug.
The next section of the report analyses market based on end user and presents the forecast in terms of value for the next ten years. The end users covered in this report are:
The next section of the report analyses the market based on indications and presents the forecast in terms of value for the next ten years. The indications covered in the report include:
Furthermore, the report analyses the market based on regions and presents the forecast in terms of value for the next ten years. Regions covered in the report include:
In addition, we have taken into consideration the year-on-year growth to understand the predictability of the market and to identify the right growth opportunities in the global antibodies market.
Another key feature of this report is the analysis of key segments in terms of absolute dollar opportunity. This is traditionally overlooked while forecasting the market. However, absolute dollar opportunity is critical for assessing the level of opportunity that a provider can look to achieve, as well as to identify potential resources from a sales and delivery perspective of the antibodies market. To understand key growth segments, Future Market Insights provides the ‘Attractiveness Index’ analysis. The resulting index helps providers to identify real market opportunities.
In the final section of the report on antibodies market, the ‘Competitive Landscape’ is included to provide report audiences with a dashboard view, to access the key differentiators among the competitor firms. Key categories of providers covered in the report are drug types. This section is primarily designed to provide clients with an objective and detailed comparative assessment of key providers specific to a market segment in the urinary tract infection value chain and the potential players with regard to the same. However, this section also includes market strategies and SWOT analysis of the main players in the market.
Detailed profiles of the medical device companies are also included in the scope of the report to evaluate their long-term and short-term strategies. Key players in the market include Novartis AG, F. Hoffmann-La Roche Ltd., Johnson & Johnson Services, Inc., Takeda Pharmaceutical Company Limited, Amgen Inc., Biogen Inc., Bristol-Myers Squibb Company, AbbVie Inc., Sanofi, Eli Lilly and Co.